DETOUR I试验:经皮股腘动脉旁路术一年结果
DETOUR I是一项前瞻性单臂多中心试验,评估PQ Bypass DETOUR系统经皮旁路治疗长段股腘动脉闭塞病变的一年安全性和有效性。共纳入78例患者(82条肢体),病变平均长度371±55 mm,96%为慢性完全闭塞,67%有严重钙化。结果显示技术成功率96%,1年一期通畅率81%±4%,Rutherford分级改善率达96%,无肺栓塞发生。
要点
- DETOUR系统经皮旁路治疗长段严重钙化股腘病变技术成功率96%
- 1年一期通畅率81%±4%,免于MAE率84%±4%
- 1年Rutherford分级改善96%,ABI平均增加0.25±0.27
核心结论
- DETOUR I试验1年结果显示PQ Bypass DETOUR系统对长段严重钙化膝上股腘病变是安全有效的经皮治疗选择。
研究设计与样本
- 前瞻性单臂多中心试验,24个月内纳入78例患者(82条肢体),病变为TASC C/D级且长度>100 mm。
- 主要安全终点为1个月内主要不良事件(MAE)率,主要有效性终点为6个月支架移植物通畅率。
主要发现
- 平均病变长度371±55 mm,96%(79/82)为慢性完全闭塞,67%(55/82)有严重钙化。
- 技术和手术成功率均为96%(79/82条肢体),1个月内无死亡或截肢,CD-TVR发生2/81条肢体(3%),免于MAE率98%(79/81)。
- 1年Kaplan-Meier一期、辅助一期和二期通畅率分别为81%±4%、82%±4%和90%±3%。
- ABI从基线到1年平均增加0.25±0.27(P < .001)。
- 1年免于支架移植物血栓形成、CD-TVR和MAE的Kaplan-Meier估计分别为84%±4%、85%±4%和84%±4%。
临床怎么用
- 对于长段严重钙化膝上股腘动脉闭塞病变,可考虑使用DETOUR系统进行经皮旁路治疗。
- 术后需关注支架移植物血栓形成和CD-TVR风险,1年免于血栓形成率84%±4%。
局限性
- 单臂设计,无对照组。
- 样本量较小(78例患者/82条肢体)。
- 随访时间仅1年,长期结果有待进一步观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to evaluate the 1-year safety and effectiveness outcomes associated with the PQ Bypass DETOUR System (PQ Bypass, Milpitas, Calif) for the percutaneous bypass of long-segment femoropopliteal occlusive disease. METHODS: This prospective, single-arm, multicenter trial enrolled patients with long-segment femoropopliteal arterial disease. The DETOUR System percutaneously deploys modular stent grafts to bypass femoropopliteal lesions through a transvenous route. Eligible patients included those with TransAtlantic Inter-Society Consensus C and D lesions >100 mm in length. The primary safety end point was the major adverse event (MAE) rate through 1 month, defined as the composite of death, clinically driven target vessel revascularization (CD-TVR), or major amputation. The primary effectiveness end point was stent graft patency through 6 months, defined as freedom from stenosis ≥50%, occlusion, or CD-TVR. RESULTS: During a 24-month period, 78 patients (82 limbs) were enrolled. The average core laboratory-measured lesion length was 371 ± 55 mm; 79 of 82 lesions (96%) were chronic total occlusions, and 55 of 82 lesions (67%) had severe calcification. The rates of technical and procedural success measured during the index procedure were both 96%, with satisfactory delivery and deployment of the device without MAEs in 79 of 82 limbs. Through 1 month, there were no deaths or amputations; CD-TVRs occurred in 2 of 81 limbs (3%), and freedom from MAEs was 98% (79/81). The 1-year Kaplan-Meier primary, assisted primary, and secondary patency rates were 81% ± 4%, 82% ± 4%, and 90% ± 3%, respectively. The ankle-brachial index increased an average of 0.25 ± 0.27 between baseline and 1 year (P < .001). Through 1 year, the Kaplan-Meier estimates of freedom from stent graft thrombosis, CD-TVR, and MAE were 84% ± 4%, 85% ± 4%, and 84% ± 4%, respectively. At 1 year, the Rutherford class improved in 77 of 80 limbs (96%), and 65 of 80 (81%) were asymptomatic. Deep venous thrombosis developed in 2 of 79 target limbs (3%) through 1 year, both at the femoropopliteal vein level. There were no instances of pulmonary embolism. CONCLUSIONS: The 1-year results from the DETOUR I trial show that the PQ Bypass DETOUR System is a safe and effective percutaneous treatment option for patients with longer, severely calcified, above-knee femoropopliteal lesions.
引用
- Krievins DK, Halena G, Scheinert D, et al. One-year results from the DETOUR I trial of the PQ Bypass DETOUR System for percutaneous femoropopliteal bypass. J Vasc Surg. 2020. PMID: 32276015. doi:10.1016/j.jvs.2020.02.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。